Elimination half-life and bioavailability of haloperidol in schizophrenic patients.

  title={Elimination half-life and bioavailability of haloperidol in schizophrenic patients.},
  author={J R Magliozzi and Leo E. Hollister},
  journal={The Journal of clinical psychiatry},
  volume={46 1},
Haloperidol was administered orally to 6 male schizophrenic patients and intravenously to 3. Elimination half-life (t1/2 beta) and bioavailability (F) were calculated for both groups from haloperidol serum concentrations determined by gas-liquid chromatography. Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23. These values were comparable to those found in normal volunteers. 

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-7 of 7 extracted citations

Population pharmacokinetics of haloperidol in terminally ill adult patients

European Journal of Clinical Pharmacology • 2017
View 10 Excerpts
Highly Influenced

Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V • 2004

Similar Papers

Loading similar papers…